Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations

Volume: 18, Issue: 1
Published: Mar 20, 2018
Abstract
Despite the remarkable advances in the early diagnosis and treatment, overall 5-year survival rate of patients with pancreatic cancer is less than 10%. Gemcitabine (GEM), a cytidine nucleoside analogue and ribonucleotide reductase inhibitor, is a primary option for patients with advanced pancreatic cancer; however, its clinical efficacy is extremely limited. This unfavorable clinical outcome of pancreatic cancer patients is at least in part...
Paper Details
Title
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations
Published Date
Mar 20, 2018
Journal
Volume
18
Issue
1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.